According to the New York Times, the new head of Pfizer plans to lay off almost 2,400 of its sales force. Could this be good news for CME funding, or just an overall cutback now that they don't have quite as much to sell as they used to? The article also says that other companies likely will follow suit. We'll have to wait and see...
0 comments
Hide comments
